Cite
HARVARD Citation
Schneeweiss, A. et al. (2020). Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast. pp. 88-95. [Online].